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New Diabetes Diagnostic Threshold of Hemoglobin
A1c and the 3-Year Incidence of Retinopathy
Yusuke Tsugawa,1 Osamu Takahashi,2 James B. Meigs,3 Roger B. Davis,1,4 Fumiaki Imamura,5
Tsuguya Fukui,2 William C. Taylor,1 and Christina C. Wee1
The new diagnostic threshold of hemoglobin A1c was made based
on evidence from cross-sectional studies, and no longitudinal
study supports its validity. To examine whether hemoglobin A1c
of 6.5% or higher defines a threshold for elevated risk of incident
retinopathy, we analyzed longitudinal data of 19,897 Japanese
adults who underwent a health checkup in 2006 and were fol-
lowed up 3 years later. We used logistic regression models and
restricted cubic spline models to examine the relationship be-
tween baseline hemoglobin A1c levels and the prevalence and
the 3-year incidence of retinopathy. The restricted cubic spline
model indicated a possible threshold for the risk of incident ret-
inopathy at hemoglobin A1c levels of 6.0–7.0%. Logistic regression
analysis found that individuals with hemoglobin A1c levels of 6.5–
6.9% were at significantly higher risk of developing retinopathy at
3 years compared with those with hemoglobin A1c levels of 5.0–
5.4% (adjusted odds ratio, 2.35 [95% CI 1.08–5.11]). Those with
hemoglobin A1c levels between 5.5 and 6.4% exhibited no evidence
of elevated risks. We did not observe a threshold in the analysis of
prevalent retinopathy. Our longitudinal results support the validity
of the new hemoglobin A1c threshold of 6.5% or higher for diag-
nosing diabetes. Diabetes 61:3280–3284, 2012
Diabetes is an increasingly important globalpublic health concern (1). An estimated 285million people, or 6.4% of the world’s population,lived with diabetes in 2010, and the number is
expected to grow to 438 million by 2030 (1). In the U.S.,
8.3% of children and adults are living with diabetes (2);
likewise, in Japan, 7.8% of the population has diabetes (3).
Recently, the International Expert Committee suggested
use of a hemoglobin A1c (HbA1c) level of 6.5% or higher as
the threshold for diagnosing diabetes (4,5). This criterion
was subsequently adopted by the American Diabetes
Association, European Association for the Study of Di-
abetes, and World Health Organization (4,5). In making its
decision, the expert panel was informed by evidence from
several cross-sectional studies that showed the association
between HbA1c level and the prevalence of retinopathy
(4–12). The outcome of retinopathy has been historically
accepted as the best criterion for comparing glycemic
measures among several complications of diabetes (13,5),
because it is a specific complication of diabetes that can be
measured objectively (13,14). Few longitudinal studies
have examined the association between HbA1c levels and
the risk of retinopathy in the general population, and these
studies do not support the validity of this new diagnostic
threshold (6,15–17). Many of the previous studies did not
adjust for independent risk factors and confounders for
retinopathy, such as age and hypertension.
To examine the validity of the new HbA1c thresholds, we
tested the hypothesis that HbA1c level of 6.5% or higher
would define a threshold for increased 3-year incidence of
retinopathy in a large cohort of Japanese adults.
RESEARCH DESIGN AND METHODS
Participants and setting.We analyzed data from a cohort of 21,137 Japanese
adults aged $21 years who underwent a health checkup between January 1
and 31 December 2006 and were followed up 3 years later at the Center for
Preventive Medicine, St. Luke’s International Hospital (Tokyo, Japan). We
used 3-year incidence of retinopathy as the outcome measure in our study
based on evidence that retinopathy develops within 5 years of diagnosis of
diabetes in substantial proportion of people with diabetes (18). The partic-
ipants underwent self-administered clinical surveys (e.g., use of the diabetes
medication, diagnosis of diabetes, family history of diabetes, smoking status,
alcohol consumption), physical examination, laboratory testing, imaging
studies, and retinal photographs.
For analysis of prevalent retinopathy, we excluded individuals without
information on baseline HbA1c (n = 375), those who did not undergo baseline
retinal exams (n = 303), and those with ungradable retinal images (n = 26),
resulting in a sample size of 20,433. For our longitudinal analysis of incident
retinopathy, we further excluded those with retinopathy at baseline (n = 245),
those missing information on follow-up retinal exams (n = 223), and those
with ungradable photographs at follow-up visits (n = 68), resulting in a final
sample size of 19,897. Institutional review board approvals were obtained from
Beth Israel Deaconess Medical Center (Boston, MA) and St. Luke’s In-
ternational Hospital (Tokyo, Japan).
Retinopathy. Retinal digital photos were taken for both eyes for the partic-
ipants at both baseline and follow-up visits. The Canon CR-DG10 digital camera
(Canon, Tokyo, Japan) was used to take one digital image per eye (total two
images per participant) through a nonpharmacologically dilated pupil. Par-
ticipants were tested in a dark room to allow the pupils to dilate naturally in
preparation for the retinal imaging examination. After dark adaptation, 45°
retinal photographs centered on the macula were taken of both eyes. The
digital images were graded by trained ophthalmologists. Retinopathy was
defined as the presence of hard exudates, cotton wool spots, retinal hemor-
rhage, or more severe forms of retinopathy, the Fukuda standard (19) A2 or
higher.
HbA1c.Whole-blood samples collected from the participants were assayed for
HbA1c immediately after the they were obtained with high-performance liquid
chromatography (Tosoh G7; Tosoh Corporation, Tokyo, Japan). We catego-
rized HbA1c levels as follows: ,5.0, 5.0–5.4, 5.5–5.9, 6.0–6.4, 6.5–6.9, and
$7.0%. Those with HbA1c levels of 5.0–5.4% comprised the largest sample and
were used as the reference category in our logistic regression models.
Other clinical variables of interest. We also extracted the potential pre-
dictors of retinopathy in those with diabetes: age (20), systolic and diastolic
blood pressures (21–26), LDL cholesterol (27), HDL cholesterol, triglycerides
(27,28), BMI, self-reported family history of diabetes, smoking status (29,30),
and alcohol consumption (31). Triglyceride levels were right-skewed; there-
fore, we used a logarithmic transformation of the variable to improve the fit
for the model. The diagnosis of diabetes was defined on based on self-report of
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a diagnosis of diabetes or of taking medication for diabetes. Hypertension was
defined as systolic blood pressure $140 mmHg, diastolic blood pressure $90
mmHg, or the use of hypertension medication. All variables, including HbA1c
and retinal images, were measured and recorded both at baseline and at
follow-up visits.
Statistical analysis. We constructed a series of logistic regression models to
investigate the association between HbA1c levels and the risk of retinopathy.
Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex,
hypertension, diagnosis of diabetes, HDL and LDL cholesterol, log-
transformed triglyceride, BMI (,25, 25.0–29.9, or $30 kg/m2), alcohol con-
sumption (regular, occasional, or never drinker), smoking status (current,
former, or never smoker), and family history of diabetes (yes or no). We
evaluated these models to estimate multivariable-adjusted odds ratios (ORs)
and 95% CIs for prevalent retinopathy (models 1a and 2a) and incident reti-
nopathy (models 1b and 2b). To examine the impact of integrating known
cases of diabetes in our analysis, we excluded those with a diagnosis of di-
abetes and developed additional models 3a and 3b, in which we adjusted for
all the variables in models 2, with the exception of the diagnosis of diabetes.
To assess whether the threshold where the risk begins to increase (inflection
point) exists, we examined the continuous associations between HbA1c level
and the prevalence or the incidence of retinopathy without assuming linearity
by fitting restricted cubic spline models (32–33) with the knots corresponding
to the HbA1c cutoff points of interest: 5.0, 5.5, 6.0, 6.5, 7.0, and 7.5%. The ORs
were adjusted for all the variables included in model 2. All statistical analyses
were conducted with SAS statistical software version 9.2 (SAS Institute Inc.,
Cary, NC).
RESULTS
Study participants. Table 1 shows the baseline charac-
teristics of the study population overall and according to
HbA1c levels. Approximately 49% were men. The mean age
was 51.0 years, the mean HbA1c was 5.6%, and the mean
(6SD) follow-up period was 3.0 6 0.29 years. Participants
with higher HbA1c levels were more likely to be older, to
be men, to smoke, to take medication for hypertension,
and to have several clinical risk factors, including elevated
blood pressure, higher BMI, lower HDL cholesterol, higher
triglyceride, and a family history of diabetes.
Prevalence of retinopathy. Among the 20,433 partic-
ipants, the crude prevalence of retinopathy was 1.2% (245/
20,433). The adjusted ORs and 95% CIs for prevalent reti-
nopathy are shown in Table 2. After initial adjustment for
age and sex (model 1a), the prevalence of retinopathy was
significantly higher at HbA1c levels $6.5% than in the ref-
erence category. After further adjustments (model 2a), this
estimate was attenuated, and only HbA1c levels $7.0%
achieved statistical significance.
Cumulative incidence of retinopathy. The crude cu-
mulative incidence of retinopathy at 3 years was 0.85%
TABLE 1
Baseline characteristics of study participants according to the HbA1c value at baseline
HbA1c categories
Overall ,5.0% 5.0–5.4% 5.5–5.9% 6.0–6.4% 6.5–6.9% $7.0%
Sample size 20,433 1,719 9,300 6,376 2,046 416 576
Baseline HbA1c (%)* 5.6 6 0.6 4.9 6 0.2 5.3 6 0.1 5.7 6 0.1 6.1 6 0.1 6.7 6 0.1 8.0 6 1.1
Follow-up HbA1c (%)* 5.7 6 0.5 5.1 6 0.3 5.5 6 0.2 5.8 6 0.2 6.1 6 0.4 6.8 6 0.7 7.5 6 1.1
Fasting blood glucose (mg/dL)* 100.6 6 15.3 93.4 6 7.2 96.2 6 7.7 100.2 6 8.5 107.0 6 11.4 123.1 6 15.5 157.5 6 39.7
Age (years)* 51.0 6 11.7 43.0 6 9.5 47.9 6 10.9 53.9 6 11.0 58.6 6 10.3 60.5 6 9.7 60.7 6 10.2
Sex (female) (%) 50.9 58.9 52.7 50.9 48.0 28.9 26.0
Systolic blood pressure
Ć (mmHg)* 119.0 6 17.6 113.7 6 16.0 116.4 6 16.7 120.6 6 17.9 124.8 6 17.8 128.1 6 18.5 130.9 6 18.0
Diastolic blood pressure
Ć (mmHg)* 73.9 6 11.3 70.4 6 10.5 72.5 6 10.9 75.1 6 11.3 77.2 6 11.2 78.9 6 11.0 80.3 6 10.9
BMI (%)†
#24.9 80.0 89.3 84.6 77.9 69.6 54.6 57.6
25–29.9 17.8 10.0 14.1 20.0 26.3 35.1 33.9
$30 2.2 0.8 1.3 2.2 4.1 10.3 8.5
Diagnosis of diabetes (%)‡ 5.3 1.6 1.4 2.8 7.5 35.3 77.3
Hypertensive treatment (%) 10.5 4.0 6.8 12.0 19.5 29.8 28.1
Family history of diabetes (%) 12.3 11.4 11.2 11.9 15.9 17.8 21.0
Fasting LDL cholesterol
Ć (mg/dL)* 119.6 6 29.9 103.6 6 26.9 115.7 6 28.9 125.5 6 29.8 129.6 6 29.2 124.5 6 29.5 127.1 6 29.8
Fasting HDL cholesterol
Ć (mg/dL)* 64.0 6 16.0 66.8 6 16.1 65.2 6 15.7 63.5 6 16.1 61.2 6 16.2 56.7 6 15.2 55.6 6 14.4
Triglycerides (mg/dL)
Median 83 67 76 88 102 112 120
Interquartile range 59–122 49–96 55–111 63–130 71–147 77–163 78–174
Serum creatinine (mg/dL)
Median 0.77 0.73 0.76 0.77 0.78 0.83 0.83
Interquartile range 0.66–0.90 0.64–0.87 0.65–0.89 0.66–0.91 0.67–0.92 0.71–0.94 0.71–0.92
Hemoglobin (g/dL)* 13.6 6 2.0 13.6 6 1.7 13.6 6 1.8 13.4 6 2.2 13.4 6 2.4 13.8 6 2.0 14.2 6 1.6
Alcohol use (%)
Regular drinker 43.6 51.4 46.2 40.2 37.2 42.2 38.0
Occasional drinker 18.0 19.2 18.8 17.7 15.2 14.3 17.4
Never 38.5 29.4 35.0 42.2 47.6 43.4 44.6
Smoking status (%)
Current smoker 14.2 13.9 13.4 14.2 15.1 18.9 20.3
Former smoker 25.0 21.8 23.6 25.7 26.5 36.5 35.1
Never smoked 60.8 64.3 63.0 60.1 58.4 44.6 44.6
*Mean 6 SD. †BMI is the weight in kilograms divided by the square of the height in meters. ‡Self-reported diagnosis of diabetes or taking
medication for diabetes.
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(170/19,897). After initial adjustment for age and sex, there
was no significant association between HbA1c value and
the incidence of retinopathy at HbA1c ,6.5%; compared
with the reference category, however, HbA1c levels of 6.5–
6.9% were associated with significantly higher risk of
developing retinopathy at 3 years (OR 2.35 [95% CI 1.08–
5.11]; P = 0.031) (Table 3). The risk remained significantly
higher after further adjusting for the confounders and
other independent risk factors for retinopathy (model 2b).
Our results did not alter substantially after the exclusion of
those with diagnosis of diabetes at baseline in model 3b.
In our analysis to evaluate whether the relationship be-
tween baseline HbA1c levels and prevalence of retinopathy
is nonlinear, we found that the nonlinear relationship was
borderline significant (P for curve = 0.08) (Fig. 1). For the
outcome of incident retinopathy, however, the nonlinear
relationship was statistically significant (P = 0.001), sug-
gesting a possible threshold at HbA1c levels between 6.0
and 7.0%. We observed a dose-response relationship be-
tween higher HbA1c levels and increased risk of incident
retinopathy at HbA1c $6.5%. The restricted cubic spline
analysis for the nondiabetic subpopulation yielded similar
findings (data not shown).
DISCUSSION
We found that Japanese adults with HbA1c levels of 6.5–
6.9% were at significantly higher risk of developing reti-
nopathy at 3 years than were those with HbA1c levels of
5.0–5.4%, whereas the risks did not increase among those
with HbA1c levels ,6.5%. To the best of our knowledge,
this is the first longitudinal study supporting the validity of
the new diagnostic threshold of HbA1c recommended by
the International Expert Committee (5,11). In contrast, we
did not observe an explicit threshold effect of HbA1c in the
analyses of the prevalent retinopathy.
Although there have been several longitudinal studies
examining the association between HbA1c levels and the
risk of retinopathy, most of those studies were limited to
samples treated for diabetes (29,34–38). There have been
only a few small longitudinal studies of general non-
diabetic populations (6,15–17). Possibly because of small
sample sizes, results from these previous studies did not
support the current HbA1c threshold for diagnosing di-
abetes (6,15–17). In the Pima Indian study (N = 927),
investigators found that the risk of incident retinopathy
begin to increase only at HbA1 levels of 9.1% (6). Only
HbA1 data were available at that time (HbA1c measure-
ments were unavailable), and no adjustments were made
for hypertension and other independent risk factors for
retinopathy in that study (6). The longitudinal study (N =
233) by van Leiden et al. (15) found that the risk of de-
veloping retinopathy was significantly higher in the highest
tertile of HbA1c (HbA1c 5.8–13.1%) relative to the lowest
tertile (HbA1c 4.3–5.2%). Because of small sample size,
these investigators collapsed HbA1c levels from 5.8 to
13.1% into a single category. Selvin et al. (16) examined the
risk of retinopathy among participants from the Athero-
sclerosis Risk in Communities study. The overall sample
size of this study was large (N = 11,357), but repeated
retinal examinations were performed in only 767 people.
These investigators were unable to detect a statistically
TABLE 2
Adjusted ORs and 95% CIs for the prevalence of retinopathy across different baseline HbA1c levels
HbA1c (%)
Individuals with and without diabetes Individuals with no diabetes
N No. of cases (%)
Model 1a* Model 2a†
N No. of cases (%)
Model 3a‡
OR 95% CI P OR 95% CI P OR 95% CI P
,5.0 1,719 10 (0.6) 1.17 0.60–2.29 0.65 1.08 0.55–2.12 0.83 1,692 10 (0.6) 1.20 0.61–2.36 0.60
5.0–5.4 9,300 67 (0.7) 1.00 Ref. Ref. 1.00 Ref. Ref. 9,170 65 (0.7) 1.00 Ref. Ref.
5.5–5.9 6,376 76 (1.2) 1.14 0.81–1.59 0.46 1.16 0.82–1.63 0.40 6,198 72 (1.2) 1.12 0.79–1.58 0.54
6.0–6.4 2,046 26 (1.3) 0.91 0.57–1.46 0.71 0.88 0.54–1.42 0.59 1,893 21 (1.1) 0.80 0.48–1.34 0.39
6.5–6.9 416 17 (4.1) 2.63 1.50–4.59 0.0007 1.81 0.98–3.37 0.060 268 5 (1.9) 1.18 0.46–3.03 0.73
$7.0 576 49 (8.5) 5.69 3.82–8.47 ,0.0001 3.02 1.71–5.34 0.0001 130 5 (3.9) 3.00 1.14–7.84 0.026
Statistically significant results at P , 0.05 are indicated in boldface. *Adjusted for age and sex. †Adjusted for age, sex, hypertension, diagnosis
of diabetes, HDL and LDL cholesterol, log-transformed triglyceride, BMI, alcohol consumption, smoking status, and family history of diabetes.
‡Adjusted for all the variables in model 2a, with the exception of the diagnosis of diabetes.
TABLE 3
Adjusted ORs for developing new retinopathy at 3 years across different baseline HbA1c levels
HbA1c (%)
Individuals with and without diabetes Individuals with no diabetes
N
No. of
cases (%)
Model 1b* Model 2b†
N
No. of
cases (%)
Model 3b‡
OR 95% CI P OR 95% CI P OR 95% CI P
,5.0 1,696 8 (0.5) 1.05 0.49–2.21 0.91 0.97 0.46–2.06 0.93 1,669 8 (0.5) 1.03 0.48–2.19 0.94
5.0–5.4 9,142 54 (0.6) 1.00 Ref. Ref. 1.00 Ref. Ref. 9,016 53 (0.6) 1.00 Ref. Ref.
5.5–5.9 6,202 51 (0.8) 1.04 0.70–1.54 0.85 1.09 0.73–1.62 0.67 6,030 49 (0.8) 1.04 0.70–1.56 0.83
6.0–6.4 1,970 18 (0.9) 0.93 0.54–1.61 0.79 1.00 0.57–1.76 1.00 1,825 17 (0.9) 0.97 0.55–1.73 0.93
6.5–6.9 388 9 (2.3) 2.24 1.08–4.65 0.031 2.35 1.08–5.11 0.031 257 6 (2.3) 2.46 1.01–5.97 0.047
$7.0 499 30 (6.0) 5.93 3.65–9.62 ,0.0001 6.45 3.21–12.93 ,0.0001 117 5 (4.3) 5.52 2.07–14.74 0.0006
Statistically significant results at P , 0.05 are indicated in boldface. *Adjusted for age and sex. †Adjusted for age, sex, hypertension, diagnosis
of diabetes, HDL and LDL cholesterol, log-transformed triglyceride, BMI, alcohol consumption, smoking status, and family history of diabetes.
‡Adjusted for all the variables in model 2b, with the exception of the diagnosis of diabetes.
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significant threshold in the association of HbA1c with the
incidence of retinopathy, possibly because of the lack of
power. Recently, Massin et al. (17) studied 700 participants
from the Data from an Epidemiological Study on the In-
sulin Resistance Syndrome study, in which participants
were followed up for 10 years, and proposed an HbA1c
threshold of 6.0%. Because retinopathy was not evaluated
at baseline in this study, however, they were not able to
examine the incidence of retinopathy (17).
Our study has several limitations. First, the retinal
images were graded in single-field photographs per eye in
this study. Multiple photographic fields per eye would have
improved the sensitivity of the funduscopic examinations.
Second, our study sample was composed exclusively of
native Japanese, so whether our results generalize to
other populations is unclear. It is noteworthy that in the
DETECT-2 project, which pooled studies from the U.S.,
Australia, India, Japan, and Singapore, they found no racial
difference in optimal HbA1c threshold (12). Third, we did
not take into account the possible effect of hemoglobin-
opathies on HbA1c values. However, the prevalence of
hemoglobinopathies in Japan is reported to be as low as
0.04% (39) and is therefore likely to have little impact on
our overall findings. Finally, the detection of an inflection
point in the relation between HbA1c and retinopathy may
not in itself establish the optimal threshold for clinicians to
use in the diagnosis and treatment of diabetes. The optimal
threshold for any patient is the level at which the benefits
of diagnosis and treatment exceed harms for that patient.
If there were only benefits and no harm in diagnosing and
treating diabetes, the inflection point would represent the
level of HbA1c. However, when the benefits of diagnosis
and treatment of diabetes are small, the optimal diagnostic
threshold may be higher than the inflection point we ob-
served.
Our longitudinal study is the first to date to suggest
a threshold of risk for incident retinopathy at a 6.5% HbA1c
level. These findings support the validity of the new di-
agnostic HbA1c threshold for diabetes recently adopted by
the American Diabetes Association, the European Ass-
ociation for the Study of Diabetes, and the World Health
Organization (5,12). Additional longitudinal studies are
needed to validate these findings in other populations.
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